GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Medicis Pharmaceutical Corporation (MRX) [hlAlert]

Rating:
Buy MRX
up 14.02 %

Medicis Pharmaceutical Corporation (MRX) rated Buy with price target $47 by Auriga

Posted on: Thursday,  Apr 26, 2012  10:25 AM ET by Auriga

Auriga rated Buy Medicis Pharmaceutical Corporation (NYSE: MRX) on 04/26/2012, when the stock price was $38.57. Since
then, Medicis Pharmaceutical Corporation has gained 14.03% as of 12/10/2012's recent price of $43.98.
If you would have followed this Auriga's recommendation on MRX, you would have gained 14.02% of your investment in 228 days.

Medicis Pharmaceutical Corporation (Medicis) is an independent specialty pharmaceutical company focused primarily on helping patients attain a healthy and youthful appearance and self-image through the development and marketing in the United States of products for the treatment of dermatological, aesthetic and podiatric conditions. It also markets products in Canada for the treatment of dermatological and aesthetic conditions. It offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles, acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, skin and skin-structure infections, seborrheic dermatitis and cosmesis. It offers 18 branded products, including PERLANE (hyaluronic acid), RESTYLANE (hyaluronic acid), SOLODYN (minocycline HCl, USP), TRIAZ (benzoyl peroxide), VANOS (fluocinonide) Cream 0.1%, and ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel. On July 1, 2008, the Company acquired LipoSonix, Inc.

Auriga operates full-service institutional equity and fixed income trading desks with state-of-the-art communications technology and trading systems. Through our U.S. corprate parent, Auriga Holdings, LLC we offer a variety of services including whole loan trading and asset management. Through our Spanish parent company, Auriga Securities Sociedad de Valores, S.A., we offer the ability to trade European equity and fixed income products. We connect electronically to buy-side firms; route orders to multiple points of execution and subsequently route to our clearing firm, Pershing, for settlement.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/26/2012 10:25 AM Buy
None
38.57 47.00
as of 12/31/2012
1 Week   
1 Month up  1.68 %
3 Months up  1.64 %
1 YTD up  14.02 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy